Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.

Abstract:

INTRODUCTION:Minimal change disease (MCD) and Focal and segmental glomerulosclerosis (FSGS) are two of the major causes of nephrotic syndrome (NS) in children and adults. According to KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, the treatment of adult primary MCD and FSGS should be based on immunosuppressants and antiproteinuric drugs. Recently, Rituximab, a humanized monoclonal antibody (mAb) has emerged as a potential treatment for steroid or calcineurin inhibitor-dependent patients; it has however demonstrated lower efficacy in those with nephrotic syndrome that is resistant to the above indicated drugs. AREAS COVERED:Analysis of ongoing and already completed clinical trials, retrieved from clinicaltrials.gov, clinicaltrialsregister.eu and PubMed involving new therapies for nephrotic syndrome secondary to MCD and FSGS. EXPERT OPINION:The most promising drugs under investigation for MCD and FSGS are mAbs. We are hopeful that new therapeutic options to treat multi-drug resistant MCD and FSGS will emerge from currently ongoing studies. What appears certain is the difficulty in enrolling patients affected by orphan renal diseases and the selection of valid endpoints in clinical trials, such as kidney failure.

authors

Siligato R,Cernaro V,Nardi C,De Gregorio F,Gembillo G,Costantino G,Conti G,Buemi M,Santoro D

doi

10.1080/13543784.2018.1540587

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

839-879

issue

11

eissn

1354-3784

issn

1744-7658

journal_volume

27

pub_type

杂志文章,评审
  • Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases.

    abstract::Prinomastat (formerly AG3340, Agouron Pharmaceuticals, Inc.) is a potent, selective oral inhibitor of matrix metalloproteinase-2, -9, -13 and -14. This peculiar selectivity should represent an advantage for prinomastat in terms of efficacy/tolerability. The drug has been shown to inhibit tumour growth and angiogenesis...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.9.2159

    authors: Scatena R

    更新日期:2000-09-01 00:00:00

  • Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.

    abstract:INTRODUCTION:IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). The clinical efficacy of tocilizumab (TCZ), a humanized anti-IL6-receptor mAb, confirmed the value of IL-6 blockade in this disease. A number of new anti-IL-6 biologics are currently in Phase I - III of clinical development for RA. A...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.912276

    authors: Semerano L,Thiolat A,Minichiello E,Clavel G,Bessis N,Boissier MC

    更新日期:2014-07-01 00:00:00

  • Developments with experimental and investigational drugs for axial spondyloarthritis.

    abstract:INTRODUCTION:Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from proinflammatory cytokines to intracellular signaling systems. The re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1337744

    authors: Clavel G,Boissier MC,Sigaux J,Semerano L

    更新日期:2017-07-01 00:00:00

  • The potential of endothelin antagonism as a therapeutic approach.

    abstract::Endothelin (ET) is a pivotal physiological regulator of blood pressure through its effects on blood vessels, heart, lung and kidneys, and the ET system can be overactive in disorders such as pulmonary hypertension, heart failure and renal disease. Such observations stimulated interest among scientists and pharmaceutic...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.11.1419

    authors: Benigni A,Perico N,Remuzzi G

    更新日期:2004-11-01 00:00:00

  • Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.

    abstract:INTRODUCTION:EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreatic cancer. Numerous drugs have been developed in order to target the tyrosine domain of EGFR as an approach in cancer treatment. AREAS COVERED:This article focuses on the different generations of EGFR tyrosi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.928283

    authors: Lee CC,Shiao HY,Wang WC,Hsieh HP

    更新日期:2014-10-01 00:00:00

  • Dronedarone: an amiodarone analogue.

    abstract::Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardia...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.4.415

    authors: Doggrell SA,Hancox JC

    更新日期:2004-04-01 00:00:00

  • Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials.

    abstract:INTRODUCTION:Current treatment for polycythemia vera (PV) is limited and primarily targets thrombosis risk. Agents targeting distinct mechanisms of action within myeloproliferation are undergoing clinical evaluation to optimize efficacy, improve tolerance and augment long term disease complications. AREA COVERED:This ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1782886

    authors: Padrnos L,Mesa R

    更新日期:2020-08-01 00:00:00

  • The therapeutic potential of CRF1 antagonists for anxiety.

    abstract::Preclinical studies suggest that the brain corticotropin-releasing factor (CRF) systems mediate anxiety-like behavioural and somatic responses through actions at the CRF1 receptor. CRF1 antagonists block the anxiogenic-like effects of CRF and stress in animal models. Cerebrospinal fluid levels of CRF are elevated in s...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.7.799

    authors: Zorrilla EP,Koob GF

    更新日期:2004-07-01 00:00:00

  • Polidocanol for endovenous microfoam sclerosant therapy.

    abstract:BACKGROUND:Polidocanol is a liquid surfactant having endothelial cell lytic properties. In the form of a controlled, dispensed microfoam it is administered endovenously as a sclerosing agent in the treatment of varicose veins. OBJECTIVE:This review summarizes efficacy of polidocanol endovenous microfoam sclerotherapy ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903376163

    authors: Eckmann DM

    更新日期:2009-12-01 00:00:00

  • An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

    abstract:INTRODUCTION:Sepsis with Bacillus anthracis infection has a very high mortality rate despite appropriate antibiotic and supportive therapies. Over the past 15 years, recent outbreaks in the US and in Europe, coupled with anthrax's bioterrorism weapon potential, have stimulated efforts to develop adjunctive therapies to...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2015.1041587

    authors: Ohanjanian L,Remy KE,Li Y,Cui X,Eichacker PQ

    更新日期:2015-01-01 00:00:00

  • Berberine: a potential phytochemical with multispectrum therapeutic activities.

    abstract:IMPORTANCE OF THE FIELD:The use of traditional medicines of natural origin is being encouraged for the treatment of chronic disorders, as synthetic drugs in such cases may cause unpredictable adverse effects. Berberine, a traditional plant alkaloid, is used in Ayurvedic and Chinese medicine for its antimicrobial and an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.517745

    authors: Vuddanda PR,Chakraborty S,Singh S

    更新日期:2010-10-01 00:00:00

  • Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.

    abstract::The clinical use of cannabinoids is currently a topic of interest not exclusively, but most importantly, concerning different areas of pain therapy. One of the major obstacles in developing clinically acceptable compounds is the cannabimimetic side-effect profile of delta-9-tetrahydrocannabinol (THC) and other cannabi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780802691951

    authors: Karst M,Wippermann S

    更新日期:2009-02-01 00:00:00

  • Toll-like receptor modulation in cardiovascular disease: a target for intervention?

    abstract::Toll-like receptors (TLRs) form a family of pattern recognition receptors that have emerged as key mediators of innate immunity. These receptors sense invading microbes and initiate the immune response. TLR-mediated inflammation is an important pathogenic link between innate immunity and a diverse panel of clinical di...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.8.857

    authors: Földes G,von Haehling S,Anker SD

    更新日期:2006-08-01 00:00:00

  • Asimadoline in the treatment of irritable bowel syndrome.

    abstract:IMPORTANCE OF THE FIELD:Irritable bowel syndrome (IBS) represents one of the most common gastrointestinal disorders, with the diarrhea-predominant form (D-IBS) representing an area of high unmet medical need. One difficulty in identifying suitable treatments for IBS is that although there are animal models for the comp...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.515209

    authors: Mangel AW,Williams VS

    更新日期:2010-10-01 00:00:00

  • Recent advances in the management of adult myositis.

    abstract::Standard drug therapy of adult polymyositis, dermatomyositis and inclusion body myositis includes high-dose corticosteroids and cytotoxic drugs (methotrexate, azathioprine (AZA) and cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immunomodulating drug in addition to corticoster...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.7.1265

    authors: Fam AG

    更新日期:2001-07-01 00:00:00

  • Pharmacological female contraception: an overview of past and future use.

    abstract::Female hormonal contraceptive methods have undergone slow change over the past four decades. Due to social, political and legal reasons, as well as medical complications, several new methods have been removed from the contraceptive armamentarium almost as quickly as they have been added. With worldwide unintended preg...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.4.449

    authors: Economidis MA,Mishell DR Jr

    更新日期:2005-04-01 00:00:00

  • Oral amphipathic peptides as therapeutic agents.

    abstract::Cholesterol can promote inflammation by its ability to stimulate the production of reactive oxygen species that result in the formation of pro-inflammatory oxidised phospholipids. High-density lipoproteins (HDLs) are part of the innate immune response and can be either pro- or anti-inflammatory independently of plasma...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.1.13

    authors: Reddy ST,Anantharamaiah GM,Navab M,Hama S,Hough G,Grijalva V,Garber DW,Datta G,Fogelman AM

    更新日期:2006-01-01 00:00:00

  • Akt inhibitors in clinical development for the treatment of cancer.

    abstract:IMPORTANCE OF THE FIELD:The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacologically modulated. As one such example, the serine-threonine kinase Akt was identified nearly two decades ago. Since then, its role in mediating multiple signaling cascades (ultimately...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.520701

    authors: Pal SK,Reckamp K,Yu H,Figlin RA

    更新日期:2010-11-01 00:00:00

  • XIAP antisense therapy with AEG 35156 in acute myeloid leukemia.

    abstract:INTRODUCTION:AEG 35156 is an antisense oligonucleotide to X-linked inhibitor of apoptosis protein (XIAP). Overexpression of XIAP is common in acute myeloid leukemia (AML) and other cancers and is thought to cause resistance to cancer therapy. Effective treatment options for patients with relapsed or refractory AML are ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.789498

    authors: Katragadda L,Carter BZ,Borthakur G

    更新日期:2013-05-01 00:00:00

  • LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action.

    abstract::Two classes of luteinising hormone-releasing hormone (LHRH) analogues have been developed so far to be used for oncological therapies: LHRH agonists and antagonists. LHRH agonists are widely and successfully used for the management of steroid-dependent malignancies. Chronic administrations of these compounds result in...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.4.709

    authors: Limonta P,Montagnani Marelli M,Moretti RM

    更新日期:2001-04-01 00:00:00

  • The treatment of urinary tract infections and use of ciprofloxacin extended release.

    abstract::Urinary tract infections (UTIs) are one of the most common reasons people seek medical attention. There are > 50% of women who will have at least one UTI during their lifetime and most of these will require a physician visit and antibiotic treatment. The high prevalence continues to the in-patient setting where genito...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.5.519

    authors: Hickerson AD,Carson CC

    更新日期:2006-05-01 00:00:00

  • Contraceptives with novel benefits.

    abstract:INTRODUCTION:Progesterone receptor (PR) agonists (progestins) and antagonists are developed for female contraceptives. However, non-contraceptive applications of newer progestins and PR modulators are being given more attention. AREAS COVERED:The newer PR agonists including drospirenone, nomegestrol, trimegestone, die...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.642368

    authors: Su Y,Lian QQ,Ge RS

    更新日期:2012-01-01 00:00:00

  • Recent advances in the development of haemoglobin-based blood substitutes.

    abstract::The term 'blood substitute' is commonly used to describe products which can carry and deliver oxygen. These products are also referred to as 'oxygen carriers' or 'oxygen therapeutics'. Blood substitutes are a new generation of oxygen therapeutics and their introduction will redefine treatment approaches in a wide rang...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.11.1659

    authors: Gulati A

    更新日期:1997-11-01 00:00:00

  • A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule.

    abstract::Helicobacter pylori infection causes peptic ulcer disease and must be regarded as a serious infectious disease. Over the past two decades treatment of the infection has been a controversial issue. Treatment is purely empirical and based on combinations of two, three or four existing drugs. Antimicrobial resistance is ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.8.1559

    authors: de Boer WA

    更新日期:2001-08-01 00:00:00

  • Aromatase inhibitors for the treatment of infertility.

    abstract::Ovarian stimulation during infertility treatment is used either alone or in conjunction with intrauterine insemination and assisted reproductive technologies. At the present time, the two main medications used for ovarian stimulation include an oral antioestrogen, clomiphene citrate and injectable gonadotrophins. In s...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.3.353

    authors: Mitwally MF,Casper RF

    更新日期:2003-03-01 00:00:00

  • Cardiac fibrosis: emerging agents in preclinical and clinical development.

    abstract:INTRODUCTION:Myocardial fibrosis is a remarkably dynamic process mediated by different molecular pathways that represent potential targets of novel therapeutic interventions. Transforming Growth Factor-beta (TGF-β), connective Tissue Growth Factor (cTGF) and Galectin-3 (Gal-3) represent the most promising targets on wh...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2021.1868432

    authors: Spoladore R,Falasconi G,Fiore G,Di Maio S,Preda A,Slavich M,Margonato A,Fragasso G

    更新日期:2021-01-04 00:00:00

  • Recent advances in natriuretic peptides in congestive heart failure.

    abstract::Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exog...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.6.643

    authors: Boerrigter G,Burnett JC Jr

    更新日期:2004-06-01 00:00:00

  • The role of telavancin in the treatment of MRSA infections in hospital.

    abstract:BACKGROUND:Serious infections caused by Gram-positive bacteria, particularly multi-drug resistant, are an important cause of morbidity and mortality in patients admitted to intensive care units. Thus, new antibiotics covering these pathogens are urgently needed. OBJECTIVE:To review characteristics of telavancin, a nov...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902845630

    authors: Bassetti M,Mikulska M,Righi E,Nicolini L,Viscoli C

    更新日期:2009-04-01 00:00:00

  • Mometasone furoate nasal spray for the treatment of asthma.

    abstract:INTRODUCTION:Asthma is a common respiratory disease characterized by airway inflammation, bronchoconstriction and airway hyperresponsiveness and symptoms such as coughing, wheezing, shortness of breath and chest tightness. Allergic rhinitis is a common comorbidity in asthma and glucocorticoids are the key stone in the ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1192124

    authors: Meteran H,Backer V

    更新日期:2016-08-01 00:00:00

  • Investigations on gossypol: past and present developments.

    abstract::Gossypol has received significant attention as a result of its potential therapeutic application as a male antifertility agent. Furthermore, recent research examining the biological activity of gossypol has revealed a number of other promising lines of enquiry. These have focused on the antitumour, antiviral and antio...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.11.1419

    authors: Dodou K,Anderson RJ,Small DA,Groundwater PW

    更新日期:2005-11-01 00:00:00